K-NK-ID101 / Abigail Wexner Research Institute, Sanofi - LARVOL DELTA

Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19 (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Kiadis Pharma; N=54 ➔ 0; Trial completion date: Nov 2021 ➔ Apr 2021; Initiation date: Apr 2021 ➔ Dec 2020; Not yet recruiting ➔ Withdrawn; Trial primary completion date: Nov 2021 ➔ Apr 2021

Clinical • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19 (clinicaltrials.gov) - P1/2; N=54; Not yet recruiting; Sponsor: Kiadis Pharma

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

Pluristyx to Support Development of Kiadis’ K-NK Cell COVID-19 Therapy Funded by $9.5 Million From the Advanced Regenerative Manufacturing Institute’s BioFabUSA Program (Businesswire) - "Pluristyx, Inc....today announced it will be supporting a collaboration between Kiadis Pharma (Kiadis), and the Advanced Regenerative Manufacturing Institute’s (ARMI) BioFabUSA program....The collaboration is funded via a $9.5 million 2020 CARES act award from ARMI’s BioFabUSA program....The funds will support a Kiadis sponsored Phase 1/2a clinical trial to evaluate K-NK-ID101....Kiadis will collaborate with ARMI/BioFabUSA to establish large-scale manufacturing capacity for K-NK-ID101....Pluristyx will also lead in development of cryopreservation processes, perform proof-of-concept studies..."

Financing • Licensing / partnership • Infectious Disease • Novel Coronavirus Disease

Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products (GlobeNewswire) - "Sanofi and Kiadis...entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of certain customary conditions) to acquire the entire share capital of Kiadis for EUR 5.45 per share, representing an aggregate adjusted equity value of €308m....K-NK002 is in a Phase 2 clinical study evaluating NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. The Phase 2 trial will be conducted in collaboration with premier U.S. transplant ce nters....Kiadis plans to initiate a phase 1/2a clinical trial evaluating use of K-NK cells to treat COVID-19 patients with government grant funding."

Licensing / partnership • New P1/2 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Kiadis announces U.S. FDA approval of the Abigail Wexner Research Institute at Nationwide Children’s Hospital’s IND for a COVID-19 clinical trial with off-the-shelf K-NK cells using Kiadis’ proprietary platforms (GlobeNewswire) - "Kiadis Pharma N.V....today announces a collaboration with the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital to develop Kiadis-NK cells (K-NK cells) as a post-exposure pre-emptive therapy for COVID-19. The U.S. Food and Drug Administration (FDA) approved AWRI’s investigational new drug application (IND) for a study....Kiadis and AWRI are developing the plan for initiation of the clinical study....'This FDA approval marks rapid progress with our K-NK-ID101 COVID-19 program and demonstrates the potential expansion with our K-NK cells into infectious disease.'"

IND • Licensing / partnership • New trial • Infectious Disease • Novel Coronavirus Disease